Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Weill Medical College of Cornell University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04843579CT.gov Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT04302324CT.gov A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | — | Active Not Recruiting | — | — | — |
NCT04287660CT.gov Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | — | Unknown | — | — | — |
NCT04063189CT.gov Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT02986451CT.gov Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | — | Withdrawn | — | — | — |
NCT02516696CT.gov BiRd vs. Rd as Initial Therapy in Multiple Myeloma | — | Terminated | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02542657CT.gov Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02575144CT.gov GEM-CLARIDEX: Ld vs BiRd | — | Unknown | — | — | — |
NCT02573935CT.gov Clarithromycin in Multiple Myeloma Induction Therapy | — | Terminated | — | — | — |
Show 12 more trialsShow fewer
NCT02188368CT.gov Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | — | Terminated | — | — | — |
NCT02624440CT.gov Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT01745588CT.gov Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01559935CT.gov Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02248428CT.gov Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT01374217CT.gov Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT01159574CT.gov Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma | — | Completed | — | — | — |
NCT00538733CT.gov Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00445692CT.gov Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | — | Completed | — | — | — |
NCT00151203CT.gov Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00182663CT.gov Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant | — | Completed | — | — | — |
NCT00006219CT.gov Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clarithromycin (this asset) | Weill Medical College of Cornell University | P3 | CCC · 55 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Clarithromycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P3 | B · 59 |
| Helicobacter Pylori Infectious Disease | — | P3 | B · 58 |
| Extrapyramidal And Movement Disease | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clarithromycin in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clarithromycin-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →